<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">Using a deep learning-based drug-target interaction model called molecular transformer-drug target interaction (MT-DTI), atazanavir, an analog of the peptide chain substrate approved for the treatment of HIV, has the potential to prevent the pro-form of SARS-CoV-2 proteins cleaving into the working form. In recent in vitro experiments, atazanavir inhibited SARS-CoV-2 replication and pro-inflammatory cytokines [
 <xref ref-type="bibr" rid="CR14">14</xref>]. Clinical trials have been launched to evaluate its anti-SARS-CoV-2 effect [
 <xref ref-type="bibr" rid="CR15">15</xref>].
</p>
